proqr.com

GENERAL
META
HTML
LINK ANALYSIS
SERVER

Proqr.com receives any estimated 215 unique visitors and 412 unique page views per day. Revenue gained from these much visits may be $0 per day from various advertising sources. The estimated worth of site is $251. Alexa global rank is 2,685,394. Maximum no. of users comes from UNITED STATES. Rank in UNITED STATES is 1,283,498.

Argeweb is ISP, hosted on IP 145.131.41.44 in Country Netherlands.

Website Age n/a
Alexa Rank no-data
Country Netherlands
IP Address 145.131.41.44

META INFORMATION

Title

ProQR - Developing RNA treatments to change the lives of patients

Description

ProQR is a clinical stage biotech company based in the Netherlands that discovers and develops unique RNA-based therapies for severe genetic disorders.

Keywords

Content Type

utf-8

No	Meta Name	Value
1	viewport	width=device-width, initial-scale=1, maximum-scale=1

google ads

GENERAL HTML INFORMATION

Type	Status
HTML 5
Responsive Website

HTML SIZE INFORMATION

Text / Code Ratio 10.50 %

proqr.com has a website text/code ratio of 10.50 %. Search engine crawlers tend to not pick up pages with inadequate content.

IMPORTANT HTML TAGS AND COUNTS

Titles

No	Text
1	We are proqr

No	Text
1	How do rna therapies work?
2	Leber’s congenital amaurosis
3	Usher syndrome type 2
4	Retinitis pigmentosa (adrp)
5	Axiomer® rna editing technology
6	Meet us

Text Styling

STRONG0
B0
EM4
I0
U0
CITE0

No	Text
1	Read more about sepofa****n for Leber's congenital amaurosis 10 and the clinical trial
2	Read more about QR-421a and QR-411 for Usher syndrome type 2
3	Read more about QR-1123 for autosomal dominant retinitis pigmentosa
4	Read more about Axiomer

LINK ANALYSIS

Total Link Count: 70

Internal Link Count : 49

No	Text	Type
1	-	image
2	Home	text
3	We are ProQR	text
4	About us	text
5	Vision 2023	text
6	Leaders***p	text
7	Careers	text
8	Contact	text
9	Science & Pipeline	text
10	Research and development pipeline	text
11	Clinical Trials	text
12	QR-1123 Aurora phase 1/2 study for adRP	text
13	Sepofa****n ILLUMINATE phase 2/3 study for LCA10	text
14	QR-421a STELLAR phase 1/2 study for Usher syndrome	text
15	Sepofa****n INSIGHT – phase 1b/2 study for LCA10	text
16	Sepofa****n Study 001 phase 1/2 for LCA10	text
17	Sepofa****n for Leber’s congenital amaurosis 10	text
18	QR-421a for Usher syndrome type 2	text
19	QR-1123 for autosomal dominant retinitis pigmentosa (adRP)	text
20	Axiomer RNA editing platform technology	text
21	Spin outs	text
22	Community	text
23	Patient and Medical Community Engagement	text
24	Eye Connect Newsletter	text
25	My Retina Tracker® genetic testing program	text
26	ProQR Expanded Access Policy	text
27	Stories	text
28	News & Publications	text
29	Posters & Publications	text
30	ProQR in the Media	text
31	Press kit	text
32	Details on the program	text
33	QR-1123 Aurora	text
34	QR-421a STELLAR	text
35	Sepofa****n ILLUMINATE	text
36	Read her story	text
37	Read their story	text
38	Read more	text
39	-	image
40	Read more about sepofa****n for Leber's congenital amaurosis 10 and the clinical trial	text
41	-	image
42	Read more about QR-421a and QR-411 for Usher syndrome type 2	text
43	-	image
44	Read more about QR-1123 for autosomal dominant retinitis pigmentosa	text
45	-	image
46	Read more about Axiomer	text
47	Disclaimer	text
48	Privacy Policy	text
49	-	empty

External Link Count : 21

No	Text	Type
1	Wings Therapeutics	text
2	Amylon Therapeutics	text
3	Press Releases	text
4	Investors	text
5	Investor Home	text
6	Press Releases	text
7	Events and Presentations	text
8	Corporate Governance	text
9	Financial Information	text
10	Share Performance	text
11	Analysts	text
12	FAQ	text
13	Email Alerts	text
14	IR Contacts	text
15	Facebook	text
16	Twitter	text
17	LinkedIn	text
18	Play "How do ProQRs RNA therapies work"	text
19	ProQR investor conference call: Interim findings Phase 1/2 clinical trial of QR-421a	text
20	Annual meeting a***ociation for Research in Vision and Ophthalmology (ARVO)	text
21	ProQR Annual General Meeting of Shareholders	text